Neurizon Therapeutics (ASX: NUZ) has dosed the first participant in the Neurizon HEALEY ALS Trial, marking the operational start of its registrational program for NUZ-001 in amyotrophic lateral sclerosis (ALS). The adaptive Phase 2/3 trial will enrol approximately 160 participants across more than 70 US clinical sites, with a 36-week treatment period and enrolment expected to complete in H2 CY2026.
Neurizon begins dosing in pivotal HEALEY ALS Platform Trial
The dosing milestone represents the commencement of Regimen I within the HEALEY ALS Platform Trial, a multicentre study conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in partnership with the Network of Excellence for ALS (NEALS). Entry into the platform is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS.
The trial structure enables Neurizon to evaluate NUZ-001 within an established clinical framework supported by leading ALS investigators and research infrastructure across the United States. This milestone confirms the program is operational and progressing toward data generation intended to support regulatory submissions.
Key trial parameters include:
- 160 participants targeted for enrolment
- 3:1 randomisation ratio (NUZ-001 to placebo)
- 10 mg/kg daily dose of NUZ-001
- 36-week treatment period per phase
- 70+ participating clinical sites in the US
- Enrolment completion expected in H2 CY2026
Managing Director and Chief Executive Officer Dr Michael Thurn described the milestone as defining for the company. “This study represents our registrational trial in ALS, a rigorous, adaptive Phase 2/3 program designed to generate the clinical evidence required to support potential regulatory submissions,” he stated.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What is a platform trial and why does this structure matter?
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) evaluates multiple investigational drugs simultaneously under a single master protocol. Multiple drug candidates, referred to as “regimens,” are tested concurrently, sharing infrastructure and operational processes across participating sites.
This design reduces the time and cost typically associated with independent trial start-up processes. By consolidating site activation, patient recruitment, and data collection under one framework, the platform accelerates study execution and delivers results more efficiently than traditional standalone trials.
Drug candidates are not automatically accepted into the platform. Expert committees review each candidate based on scientific data packages, mechanism of action, and evidence of potential therapeutic benefit. Selection into the platform validates that NUZ-001 met these scientific criteria and was deemed worthy of evaluation alongside other investigational therapies.
The trial is conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham in partnership with NEALS, providing access to the most established ALS clinical research networks in the United States. For Neurizon, this structure offers operational efficiency and access to leading investigators while maintaining the regulatory rigour required for potential approval pathways.
Trial design targets disease progression and survival endpoints
Regimen I consists of two phases: a 36-week randomised controlled treatment (RCT) phase followed by a 36-week active treatment extension (ATE) phase. During the RCT phase, participants receive either daily NUZ-001 at 10 mg/kg or placebo at a 3:1 ratio. In the ATE phase, all participants receive active treatment with NUZ-001, providing up to 72 weeks of total treatment data.
The primary endpoint evaluates change from baseline through Week 36 in disease severity, measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score and survival. Secondary endpoints include additional measures of disease progression, such as respiratory function via slow vital capacity (SVC), and survival through Week 36.
| Phase | Duration | Treatment | Endpoint Focus |
|---|---|---|---|
| RCT Phase | 36 weeks | NUZ-001 vs placebo (3:1) | Efficacy + safety |
| ATE Phase | 36 weeks | NUZ-001 (all participants) | Extended safety/efficacy |
The ALSFRS-R is the gold-standard assessment tool used in ALS clinical trials and is accepted by the US Food and Drug Administration (FDA) for evaluating disease progression. The scale measures functional decline across domains including speech, swallowing, motor function, and respiratory capacity. Inclusion of survival as a co-primary endpoint alongside ALSFRS-R elevates the regulatory relevance of the trial, as positive results on both measures would carry significant weight in approval discussions.
The adaptive Phase 2/3 design allows for interim analyses and potential modifications to the trial based on accumulating data, subject to regulatory agreement. This structure provides flexibility while maintaining scientific rigour, enabling the program to respond to emerging efficacy or safety signals during execution.
Phase 1 results underpin the pivotal program
Neurizon’s entry into the HEALEY ALS Platform Trial follows completion of a Phase 1 clinical program in 12 people living with ALS. That earlier study showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated. The Phase 1 data package, combined with findings from an Open Label Extension study, formed the scientific basis for expert committee review and acceptance into the platform.
Dr Thurn noted the importance of this validation. “Entry into the HEALEY ALS Platform Trial reflects our scientific data package and the favourable safety and tolerability profile observed in our Phase 1 and Open Label Extension studies,” he stated.
The Phase 1 program represents a critical de-risking milestone. Early-stage safety and tolerability findings reduce the likelihood of unexpected adverse events in larger populations, while preliminary efficacy signals provide confidence that NUZ-001’s mechanism may translate into measurable clinical benefit. The competitive selection process for platform entry requires review by independent experts, adding external validation to Neurizon’s internal assessment of the data.
Dr Michael Thurn, Managing Director and Chief Executive Officer
“Entry into the HEALEY ALS Platform Trial reflects our scientific data package and the favourable safety and tolerability profile observed in our Phase 1 and Open Label Extension studies.”
Timeline and next steps for investors
Enrolment in Regimen I is expected to complete in H2 CY2026, with the 36-week treatment period commencing upon randomisation of each participant. Primary endpoint data readout would occur approximately 36 weeks following completion of enrolment, positioning potential topline results for late 2026 or early 2027, subject to enrolment pace and operational timelines.
The trial structure includes ongoing engagement with regulatory authorities, including the FDA, as the program progresses. This dialogue enables Neurizon to align data generation with regulatory expectations and potentially expedite review processes if results support a regulatory submission.
Key milestones for investors to monitor:
- Enrolment progress updates through 2026
- Enrolment completion (H2 CY2026)
- Primary endpoint data readout (approximately 36 weeks post-enrolment)
The registrational positioning of this trial means success in the primary endpoint could support regulatory filings. For investors, first dosing represents operational de-risking, confirming the trial has moved from planning to active execution. Enrolment pace will be a critical metric, as faster recruitment would accelerate the timeline to data readout and potential commercialisation.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What this means for NUZ-001’s commercial potential
ALS is a progressive neurodegenerative disease with limited treatment options. Current approved therapies provide modest benefits, creating an opportunity for new mechanisms that demonstrate meaningful clinical impact.
The HEALEY ALS Platform Trial provides Neurizon with access to leading ALS investigators, established clinical infrastructure, and a patient population actively engaged in clinical research. This positions NUZ-001 for efficient data generation within a framework recognised by regulators and the ALS research community.
Professor Merit Cudkowicz, Principal Investigator of the HEALEY ALS Platform Trial and Director of the Sean M. Healey & AMG Center for ALS at Mass General Brigham, emphasised the collaborative nature of the program.
Professor Merit Cudkowicz, Principal Investigator, HEALEY ALS Platform Trial
“Beginning enrolment is a significant step for the regimen, and would not be possible without the dedication of people living with ALS and their families, collaborators, and our top trials sites.”
Successful completion of Regimen I with positive results on ALSFRS-R and survival endpoints could position NUZ-001 for an FDA approval pathway. The platform structure, combined with regulatory engagement built into the trial design, positions Neurizon for efficient discussions with authorities if data supports progression to commercial approval.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors receiving FREE breaking ASX biotech news within minutes of release, complete with in-depth analysis. Get real-time alerts on clinical trial results, regulatory milestones, and drug development progress delivered straight to your inbox. Click the “Free Alerts” button at Big News Blast to stay ahead on biotech news.